"Infleqtion Quantum" The SPAC is back, and, I believe this one could be quite lucrative as this pioneer of Quantum Sensing Technology goes public!!

 

Here’s a retail-friendly investment/business snapshot of Infleqtion 

(going public via Churchill Capital Corp X – “CCCX”)

plus a quick peer check vs IONQ, D-Wave (QBTS), and Rigetti (RGTI).

Churchill Capital Corp X (CCCX)

$12.17

+$0.82(+7.29%)September 19

Infleqtion (ticker to be: INFQ after merger) — Retail Cheat Sheet

What Infleqtion is

Neutral-atom “full-stack” quantum company that sells precision sensors (clocks, RF, inertial/GPS-denied nav) and quantum computing systems, with software to tie it together. The SPAC deal values Infleqtion at ~$1.8B pre-money and aims to list as INFQ after closing. Reuters+1

Why now (deal basics & cash)

• Transaction: Infleqtion to merge with CCCX; post-close ticker expected: INFQ (Nasdaq). Shareholder vote + SEC clearance required. SEC

• Proceeds: “> $540M expected gross proceeds” (includes ~$416M trust, >$125M PIPE). Actual cash depends on redemptions. PIPE backers cited include Maverick Capital and Morgan Stanley’s Counterpoint Global (plus others). Yahoo Finance+2The Quantum Insider+2

• Use of funds: accelerate product roadmap, manufacturing scale-up, and go-to-market. The Quantum Insider

Commercial traction (what’s real today)

• Revenue (TTM to Jun 30, 2025): ~$29M; 2025E booked & awarded business ~ $50M; identified pipeline > $300M (company figures; prelim/unaudited). Quantum Computing Report+1

• Customers/partners called out: NASA, U.S. DoD, U.K. government, and NVIDIA among others. Nasdaq+1

• Tech milestones (company-stated): neutral-atom platform with record qubit arrays, high two-qubit fidelities, early logical-qubit demos; sensors already shipped in volume (hundreds). The Quantum Insider

Institutional & transaction parties (high level)

• PIPE investors (named in press/PR): Maverick Capital, Counterpoint Global (Morgan Stanley), plus Glynn Capital, BOKA Capital, LCP Quantum (per deal comms). The Quantum Insider

• Advisors: Citi (capital markets advisor/PIPE placement), J.P. Morgan (advisor/PIPE), BTIG; multiple law firms. The Quantum Insider

---

How Infleqtion stacks up vs public quantum peers

Company	Core tech & focus	Where $ comes from now	Recent scale markers
Infleqtion (INFQ, post-deal)	Neutral atoms; sensing (clocks/RF/inertial) + computing	Government/defense + enterprise; sells hardware & systems; software	TTM rev ~$29M; booked/awarded ~$50M 2025E (company est.) Quantum Computing Report+1
IonQ (IONQ)	Trapped-ion quantum computing	Cloud QPU access, services, systems	Larger public market cap today; raised significant capital; pure computing focus. (See investor deck comps.) Churchill Capital X Corp
D-Wave (QBTS)	Quantum annealing (optimization), moving toward “advantage2”	Cloud/hybrid annealing services; enterprise pilots	Smaller revenue base than Infleqtion per deck comps; meaningful enterprise logos. Churchill Capital X Corp
Rigetti (RGTI)	Superconducting gate-model	Cloud access, government R&D, systems	Similar early-stage commercialization; comps show lower LTM revenue. Churchill Capital X Corp

Deck comparison slide shows Infleqtion LTM revenue ~$29M vs IONQ $52M, D-Wave $22M, Rigetti $8M as of 6/30/25 (company/FactSet notes; prelim and subject to change). Churchill Capital X Corp

Live trading context (today): IONQ ~$70, QBTS ~$27, RGTI ~$29, CCCX ~$12 (can be volatile around deal milestones). (Prices from the market feed above.)

---

Simple thesis (retail version)

Bull case (what could go right):

• Quantum sensing has nearer-term use (GPS-denied nav, timing, RF) -> revenue earlier than pure computing. Government/defense demand is a strong tailwind. Nasdaq

• Platform leverage: one neutral-atom “core” to serve both sensing + computing -> diversified revenue and cross-learning. The Quantum Insider

• Capitalized via SPAC + PIPE to scale production and delivery. Yahoo Finance

Bear case (key risks):

• De-SPAC risk: redemptions/dilution; post-merger selling pressure common in SPACs. SEC

• Execution/SWaP-C: shrinking lab systems into rugged, cost-effective field units is hard; procurement cycles can be long. (Industry analyses flag manufacturability & adoption hurdles.) datacenterdynamics.com

• Competition & valuation volatility across quantum names.

---

How to invest (plain English)

1. Before the merger closes: buying CCCX common gives you exposure. If the deal closes and you do not redeem, your CCCX shares become INFQ automatically at closing. There will be a shareholder vote and a redemption window disclosed in the SEC S-4/proxy. SEC

2. At/after conversion: ticker should switch to INFQ; trading can be volatile in the first weeks. SEC

3. Position sizing (retail rule-of-thumb): treat as early-stage growth—size modestly (e.g., 0.5–2% of portfolio per name), add on execution catalysts (new contracts/shipments) rather than price spikes.

4. Catalysts to watch: SEC S-4 effectiveness, shareholder vote, redemption results, first major shipment(s) of sensors/nav systems, new defense/space awards, computing milestones (logical-qubit progress). SEC+1

---

Bottom line (my take)

If you want nearer-term quantum exposure tilted to sensing + dual-track computing, Infleqtion offers a differentiated approach and real (if early) revenues vs peers. The risk is high (it’s still deep-tech + SPAC dynamics), but the setup is credible: named government customers, growing bookings, and fresh capital. For a diversified retail portfolio, a starter position held through the conversion—with eyes on redemption levels and first post-close execution—makes sense if you accept volatility and a multi-year horizon. Quantum Computing Report+2Yahoo Finance+2

---

Ed Note: How are we investing in Infleqtion?

We bought shares of CCCX @ $10.70 and plan to hold them through the conversion process.  

If, after conversion, there is a drop in share price of INFQ, we will be adding to our small position.(1.5%)

Sources & references

• SEC deal communications / 425 & S-4 plans (mechanics, vote/redemptions). SEC+1

• Company/press & investor info (deal size, partners, revenue, PIPE names). Yahoo Finance+2The Quantum Insider+2

• Investor presentation (peer comps, LTM revenue, booked business, transaction overview). Churchill Capital X Corp+1

  Quantum Tech leader, Infleqtion reports will go public via SPAC - How to invest!

Why do Nvidia and so many institutional investors own most of the shares of RXRX - Recursion Pharma

 

Why Nvidia Invested in RXRX

1. Deep AI Integration for Drug Discovery

• In July 2023, Nvidia invested $50 million via a PIPE deal to help Recursion accelerate training of AI models for drug discovery. This investment boosted RXRX stock by about 83% immediately Reuters

• Nvidia provided cutting-edge GPUs and access to its BioNeMo generative-AI cloud platform so Recursion could train models on its massive biological dataset MarketWatch+2.

2. Equity Stake & Strategic Synergy

• Nvidia now holds over 7.7 million shares—approximately a 3–4% stake—making Recursion one of its top non-core holdings The Times+11

• This aligns with Nvidia’s broader strategy of investing in AI-first companies that complement its hardware, not just selling chips.

3. Accelrating RXRX’s Supercomputer Ambitions

• Recursion built BioHive‑2, a supercomputer powered by Nvidia’s DGX H100 GPUs. It delivers a 4x speed increase over their prior system, enabling faster model training Reuters+2T

• This partnership helps validate Nvidia hardware in high-performance biotech applications—which can drive future sales to pharma partners.

---

🏥 Broader Vision: Redefining Pharma with AI

• Recursion uses AI, automation, and robotics to develop drugs more quickly and affordably. Its platform includes the “virtual cell” paradigm and is backed by major pharma companies like Bayer and Roche Investors+14.

• Analysts project RXRX revenue growing at a ~65–73% CAGR through 2027—significantly above typical biotech growth—with Nvidia’s backing lending extra credibility The Motley Fool+5

✅ Summary

Nvidia's investment in RXRX is twofold:

1. Financial Buy-In – it gains exposure to a high-growth biotech using AI and fosters long-term capital appreciation.

2. Strategic Alignment – Nvidia deepens integration of its AI stack (hardware + BioNeMo) in the drug discovery workflow, while demonstrating its systems’ performance in real-world pharma applications.

It’s part of a broader strategy of deploying capital into AI-first companies that can both benefit from and validate Nvidia’s ecosystem, accelerating adoption across industries.

---

Here are the top ten institutional investors in Recursion Pharmaceuticals (RXRX), based on the most recently reported 13F filings (as of March 31, 2025) and aggregated data sources Yahoo Finance+12:

---

🏦 Top 10 Institutional Holders of RXRX

Ranked by percentage ownership:

1. ARK Investment Management LLC — 8.66% (~34.8M shares; ~$184 M) 

2. Vanguard Group Inc. — 8.03% (~32.3M shares; ~$171 M) 

3. Lux Ventures IV LP — 7.46% (~30.3M shares; ~$194 M) 
   

   4. Baillie Gifford & Co. — 6.07% (~24.4M shares; ~$129 M)

4. BlackRock Inc. — 5.78% (~23.5M shares; ~$150 M) 

5. SoftBank Group Corp. — 3.61% (~14.7M shares; ~$94 M) 

6. Kinnevik AB (publ) — 3.30% (~13.4M shares; ~$86 M) 

7. State Street Corp. — 3.22% (~13.1M shares; ~$84 M) 

8. Mubadala Investment Co. PJSC — 3.19% (~13.0M shares; ~$83 M) 

9. Novo Holdings A/S — 2.38% (~9.7M shares; ~$62 M) 

🧾 Summary Table

Investor	% Ownership	Approx. Shares
ARK Investment Management LLC	8.66%	~34.8 M
Vanguard Group Inc.	8.03%	~32.3 M
Lux Ventures IV LP	7.46%	~30.3 M
Baillie Gifford & Co.	6.07%	~24.4 M
BlackRock Inc.	5.78%	~23.5 M
SoftBank Group Corp.	3.61%	~14.7 M
Kinnevik AB (publ)	3.30%	~13.4 M
State Street Corp.	3.22%	~13.1 M
Mubadala Investment Co. PJSC	3.19%	~13.0 M
Novo Holdings A/S	2.38%	~9.7 M

---

💡 Key Insights

• Institutional investors control around 75% of RXRX's outstanding shares Nasdaq+

• ARK and Vanguard are the two largest, with each holding over 8% of the company.

• Lux Ventures IV LP—a prominent insider-linked investor—is effectively the third-largest stakeholder at ~7.5%.

• Other heavyweights include Baillie Gifford, BlackRock, SoftBank, and sovereign/strategic holders like Mubadala and Novo Holdings.

---

Here’s a breakdown of the recent moves by institutional investors in RXRX:

---

📈 Increased Positions (Recent Quarter)

• UBS Asset Management Americas (UBS AM) added 4.15M shares (+183.7%) in Q1 2025 (~$22M) MarketBeat+

• UBS Group AG boosted its stake by 2.57M shares (+85.4%) (~$13.6M) 

• According to CapEdge filings (as of July 22, 2025):

  • KLP Kapitalforvaltning AS increased by +20% (~61K shares)

  • Steel Peak Wealth Management up +21% (~85K shares)

  • Prime Capital Investment Advisors boosted by +61% (~30K shares)

  • IMC‑Chicago surged +76% (~284K shares) 

📉 Reduced or Exited Positions

• RA Capital Management, L.P. fully exited its position, selling 7.73M shares (~$41M) in Q1 2025 

• CapEdge data shows QRG Capital Management reduced its holding by 32% (~19K shares) as of July 21, 2025 

🔍 Additional Context

• Total institutional inflows over the past 24 months reached significantly more than outflows:

  • 83.2M shares purchased (~$550M)

  • 18.3M shares sold (~$117M) MarketBeat

  • This reflects overall upward interest, but pockets of profit-taking and rotation remain.

• Other Q1 fourth-quarter buyers included firms like Brighton Jones, Victory Capital, and Private Advisor Group, while sellers included RA Capital prominently MarketBeatMarketBeat.

---

✅ Summary

• UBS (both global and Americas units) made the largest scale-ups recently.

• RA Capital initiated the most substantial reduction, liquidating its entire stake.

• Mid-cap managers like KLP, Steel Peak, Prime Capital, and IMC‑Chicago also significantly expanded their RXRX positions.

• Some smaller managers, including QRG Capital, reduced or trimmed their positions.

  
  
  

• ED Note:  We are long RXRX

Robots, Robotics and Automation - Investing in the "picks and shovels"!

 

If I had to pick only one "pick and shovel" stock to invest in for the robotics (especially humanoid/industrial robot) boom—including plays like Tesla's Optimus—my choice is:

---

🏆 Rockwell Automation (NYSE: ROK)

🔧 Why Rockwell?

1. Pure-play industrial automation leader

• Rockwell is deeply embedded in manufacturing, robotics integration, motion control, industrial sensors, and factory digitization.

• Its FactoryTalk, ControlLogix, and Allen-Bradley product lines are widely used in industrial robotics—from automotive to food production.

2. Strategic partnerships with AI & cloud giants

• Rockwell has deep integrations with Microsoft Azure, NVIDIA Omniverse, and PTC (IoT CAD software)—vital for robotic design, simulation, and operation.

3. Robotics-native clients

• Customers include Tesla, Boeing, Procter & Gamble, and automation integrators. Optimus-style humanoid robots will require factory retooling—which Rockwell enables.

4. Strong financials

• High margins (~25% EBITDA), consistent free cash flow, and a track record of innovation make it a rare combo of growth, quality, and income (1.6% dividend yield).

• Rockwell is profitable, with global exposure and minimal debt pressure.

5. Long-term megatrends tailwind

• Growth in "lights-out factories", robotic arms, machine vision, and motion automation all converge at Rockwell.

• As companies transition from legacy automation to AI-enhanced robotic systems, Rockwell provides the tools, software, and integration layers.

---

✳️ Quick Stats (as of June 2025)

Metric	Value
Market Cap	~$32B
Dividend Yield	~1.6%
P/E Ratio	~28x
YoY Revenue Growth	~6%
Robotics/Automation %	>75% of revenue

---

🆚 Why Not Others?

• Ametek (AME) and RBC Bearings (RBC) are great precision motion plays—but more passive in robotic development.

• NVIDIA is critical—but not a pure "pick and shovel" for robotics. It's broader AI and data center focused.

• ABB, Keyence, and Siemens are also excellent—but either not U.S.-based or less pure-play.

• Ouster (LiDAR) and Regal Rexnord (motors) are too narrow.

---

✅ Final Word

If you're investing in the tools behind the robotics revolution, especially as it scales into humanoids like Tesla's Optimus, Rockwell Automation stands out as the most strategic, financially sound, and robotics-focused pick-and-shovel stock available today.

Rockwell Automation Inc (ROK)

$321.80

+$107.21(+49.96%)Past 5 years

Here’s a detailed breakdown of Rockwell Automation (ROK), covering earnings projections and technical valuation insights:

---

📈 5-Year Earnings & Growth Forecast

Period	Projected EPS Growth
Next 1 yr (to 2026)	From ~$7.97 today to ~$9.73 → ~22% increase
2026 Estimate	~$11.31 EPS
2027 Estimate	~$13.17 EPS
CAGR (2025–2028)	EPS +14.2% / revenue +6.2% annually
Long-term (to 2029)	Analysts forecast ~$14.11 EPS by FY 2029  Analyst Consensus: About 6‑11 analysts expect EPS between $9–10 for FY 2025 and rising steadily through 2027 .

---

📊 Technical Analysis Snapshot

• Moving Averages:

  • On the daily scale, price is above 200‑day MA (~$277), 50‑day (~$283), and 20‑day (~$317), indicating a bullish trend 

  • Short‑term MAs also bullish in most models .

• Trend & Patterns:
  ChartMill gives a technical rating of 9/10, with both short- and long-term trends positive.
  A bull-flag pattern suggests a potential buy-on-breakout opportunity, with support around $318 and resistance near $325 

• Indicators:

  • RSI is neutral-to-strong — around mid‑range.

  • MACD recent crossover turns positive, supporting bullish momentum in daily models .

  • Investor’s Business Daily (IBD) upgraded RS rating to 83 (top quintile) but noted a slight pullback from a failed base entry near $308, implying a new base formation may be prudent 

---

🔍 Long-Term Outlook & Valuation

• Earnings Growth Driver: Rockwell provides industrial automation solutions, benefiting from onshoring and the broader digitization of manufacturing. Barron’s highlights projected ~17% annual EPS growth through 2027 

• Tariff Tailwinds: Rockwell is cited as a key beneficiary of increased onshoring due to higher tariffs, making it a go-to industrial play in that trend .

• Valuation Summary:

  • Trading near $322, with a one-year average price target of $326 (range $290–371) by Wall Street 

  • Reasonable P/E based on ~$9–10 EPS, giving ~30×–35× forward P/E—typical for a high-quality industrial automation company.

---

🧭 Bottom Line

• Earnings Trajectory: Robust growth expected — ~14–22% EPS CAGR over next 2–5 years.

• Technical Setup: Bullish trend with backup from multiple indicators and chart patterns, though a careful entry after base confirmation may yield better risk/reward.

• Macro-Catalysts: Onshoring, increased automation, and high-margin solutions support earnings and valuation.

---

✅ Your Next Moves

• For long-term exposure: Buying on dips above $318–$320 with a multi-year view of automation trends—and holding for EPS growth and rising automation adoption.

• For tactical entries: Monitor a breakout above $325 on expanding volume—this would confirm bullish momentum and enable tighter, disciplined entries.

Here’s a refined model for a 12-month target price on Rockwell Automation (ROK):

---

📊 1. Base Scenario: Conservative PE

• EPS Estimate for FY2026: ~$11.49 

• Modest Forward P/E: 26× (near its historical fair ratio of ~29×)

• Target Price: 11.49 × 26 ≈ $299

This projection is slightly below current levels, suggesting limited upside if the market is cautious.

---

🔼 2. Growth Scenario: Elevated PE

• Same EPS: $11.49

• Premium P/E: 30× (reflecting continued automation enthusiasm)

• Target Price: 11.49 × 30 ≈ $345

This targets the upper range of analyst forecasts and assumes multiple expansion 

---

🛠 3. Bull Case: Full Growth Re-Rating

• EPS for FY2027: ~$13.19 

• High-End P/E: 28× (middle ground between growth and valuation)

• Target Price: 13.19 × 28 ≈ $370

This aligns with the top analyst estimate ($371) .

---

📌 Summary Table

Scenario	Assumed EPS	P/E Multiple	Target Price
Base	$11.49	26×	$299
Growth	$11.49	30×	$345
Bull (2027)	$13.19	28×	$370

---

🔍 Interpretation

• Base Case (~$300): Reflects stable earnings and modest market sentiment.

• Growth Case (~$345): Possible if automation tailwinds continue and valuation stays robust.

• Bull Case (~$370): Requires strong execution, EPS delivery, and renewed investor enthusiasm.

  Did Desjardin just Release the Kraken? - Kraken Robotics Investment and Business Report (June 2025)